Lates News

According to the A-shares AI news, Minsheng Securities released a research report on April 30, giving a buy rating to Chuan Ning Bio (301301.SZ). The rating reasons mainly include: 1) Splitting of 2024 performance: The main business of 2024 continued to be strong, with three major intermediate production lines maintaining rapid growth year-on-year; 2) Interpretation of 2025 Q1 performance: Q1 performance narrowed year-on-year, mainly due to the decrease in penicillin prices and cost increase; 3) Main business: Prices of main varieties are expected to remain stable, AI technology empowerment + strategic inventory reserves are expected to improve performance resilience; 4) Synthetic biology: The selection of products and research and development capabilities have been validated, and the volume of the second curve business of synthetic biology is about to increase. (Daily Economic News)